Newmanbrain at WMF – We Make Future 2025 in Bologna, Italy
This week, our CEO Pablo Belmonte will be representing Newmanbrain at WMF – We Make Future 2025, Europe’s largest international festival dedicated to artificial intelligence, technology, and digital innovation.
Newmanbrain Showcases Cutting-Edge Neurotechnology at eMerge Americas 2025
NewmanBrain unveiled its Theia device for mild cognitive impairment at eMerge Americas 2025, showcasing its advanced technology and global reach.
Theia AI-Powered fNIR Technology for MCI Detection at LSI USA 2025
Theia, an AI-powered fNIR technology for non-invasive detection of mild cognitive impairment (MCI), was unveiled at LSI USA 2025.
II Women and Technology Congress
Last Friday, February 14th, Newmanbrain had the privilege of participating in the II Women and Technology Congress in Alicante, organized by Aepa (Association of Women Entrepreneurs, Professionals, and Executives of Alicante).
Newmanbrain at the JP Morgan Healthcare Conference
Pablo Belmonte, newmanbrain CEO, is attending the prestigious JP Morgan Healthcare Conference in San Francisco, the most renowned healthcare event in the U.S.
3rd edition of the Longevity World Forum
Newmanbrain attended the 3rd edition of the Longevity World Forum in Alicante with its Theia device.
LSI Europe 2024 in Portugal: Innovation, Investment, and Newmanbrain’s Role in the European Medtech Ecosystem
LSI Europe 2024 brought investors and innovators to Portugal, where Newmanbrain highlighted how AI and neurotechnology are advancing early cognitive assessment in Europe.
Brain Awareness Week 2024
A wonderful and enriching debate organized by the Institute of Neurosciences focused on AI applied to neuroscience and medicine. Our key partner, Dr. Joaquín Ibáñez, shared his experience as a speaker. Stay up-to-date with the latest advancements in this exciting field.
XV Congreso Nacional de Neuropsicología FANPSE 2024
PDF Document
VII Edition Chemostart
After the presentation of 71 high-quality projects, Newmanbrain has been pre-selected in the VII Edition of the ChemoStart Program for its proposal of the THEIA™ functional Near Infrared Spectroscopy (fNIRs) device.